FCM
YMAB

Flinton Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Flinton Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$47K Sell
1,802
-680
-27% -$17.4K ﹤0.01% 826
2019
Q2 		$57K Sell
2,482
-1,700
-41% -$39K ﹤0.01% 825
2019
Q1 		$110K Hold
4,182
– – ﹤0.01% 762
2018
Q4 		$85K Sell
4,182
-4,692
-53% -$108K ﹤0.01% 762
2018
Q3 		$236K Buy
+8,874
New +$226K 0.01% 674

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flinton Capital Management's YMAB Position: Q3 2019 in Review

Flinton Capital Management reduced its Y-mAbs Therapeutics (YMAB) stake by 27% in Q3 2019, selling an estimated $17.4K and leaving 1,802 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Flinton Capital Management first reported a position in YMAB in Q3 2018 and has held it in 5 quarters since. The position peaked at $236K in Q3 2018. 65 funds tracked by Wall St. Rank hold YMAB as of Q3 2019.

  • Flinton Capital Management held 1,802 shares of Y-mAbs Therapeutics worth $47K as of Q3 2019.
  • Flinton Capital Management sold 680 Y-mAbs Therapeutics shares in Q3 2019, an estimated $17.4K.
  • Y-mAbs Therapeutics made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #826 holding.
  • Flinton Capital Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and has held it in 5 quarters since.
  • Flinton Capital Management's Y-mAbs Therapeutics position peaked at $236K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.